Identifying acutely ill medical patients requiring thromboprophylaxis

*Service Quality of Care, Geneva University Hospitals and Faculty of Medicine, Geneva; Sanofi-Synthelabo (Switzerland), Meyrin; and Divisionof Angiology and Hemostasis, Geneva University Hospitals and Faculty of Medicine, Geneva, SwitzerlandTo cite this article: Chopard P, Spirk D, Bounameaux H. Identifying acutely ill medical patients requiring thromboprophylaxis. J Thromb Haemost2006; 4: 915–6.

[1]  J. Cornuz,et al.  Pharmacological thromboembolic prophylaxis in a medical ward , 2002, Journal of General Internal Medicine.

[2]  J. Bergmann,et al.  Venous thromboembolism in the medically ill patient: a call to action , 2005, International journal of clinical practice.

[3]  D. Hayoz,et al.  Venous thromboembolism prophylaxis in acutely ill medical patients: definite need for improvement , 2005, Journal of internal medicine.

[4]  Clifford W Colwell,et al.  Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.

[5]  S. Goldhaber,et al.  Randomized, Placebo-Controlled Trial of Dalteparin for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients , 2004, Circulation.

[6]  A. Panju,et al.  Venous thromboembolism prophylaxis in medical inpatients: a retrospective chart review. , 2003, Thrombosis research.

[7]  P. Chopard,et al.  An evaluation of thromboembolism prophylaxis in acutely ill medical patients. , 2002, Swiss medical weekly.

[8]  A. Turpie,et al.  A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. , 1999, The New England journal of medicine.

[9]  G. Chatellier,et al.  [Evaluation of an intervention on the prescription and biological surveillance of low-molecular weight heparins in medicine]. , 1996, Presse medicale.

[10]  J. Heit,et al.  Prevention of venous thromboembolism. , 1995, Chest.